- Home
- JLS vs GNLX Comparison
JLS vs GNLX Comparison
Compare JLS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | GNLX |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 110.4M |
| IPO Year | 2009 | 2022 |
Fundamental Metrics
Financial Performance| Metric | JLS | GNLX |
|---|---|---|
| Price | $16.15 | $2.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 17.1K | ★ 266.4K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $2.29 |
| 52 Week High | $19.03 | $8.54 |
Technical Indicators
Market Signals| Indicator | JLS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 18.12 | 45.64 |
| Support Level | N/A | $2.32 |
| Resistance Level | $18.66 | $2.86 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 0.00 | 47.62 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.